Clinical Trial Update: Post-Market Study of Low-flow ECCO2R Using PrismaLung+ [NA]

View source ↗

Summary

Post-market study evaluating low-flow ECCO2R using PrismaLung+ for mild to moderate acute respiratory distress syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Snippet

Sponsor: Vantive Health LLC | Conditions: Mild to Moderate Acute Respiratory Distress Syndrome | NA | Status: COMPLETED